Skip to main content

IMPLICACIONES CLINICAS DE LOS PERFILES DE EXPRESION GENICA EN SANGRE PERIFERICA EN EL CANCER DE PROSTATA METASTASICO

PI18/00883

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
Execution centre INSTITUTO MURCIANO DE INVESTIGACION BIOSANITARIA (IMIB)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

  • Fernandez-Perez, María P.
  • Perez-Navarro, Enrique|||0000-0003-1091-8926
  • Alonso-Gordoa, Teresa|||0000-0002-8966-7236
  • Conteduca, Vincenza|||0000-0002-6921-714X
  • Font, Albert|||0000-0003-3908-1111
  • Vázquez-Estévez, Sergio
  • González-del-Alba, Aránzazu|||0000-0001-6570-009X
  • Wetterskog, Daniel
  • Antonarakis, Emmanuel S.
  • Mellado, Begoña|||0000-0002-8088-5966
  • Fernández Calvo, Ovidio|||0000-0001-5283-9754
  • Mendez Vidal, María José|||0000-0002-7460-1859
  • Climent, Miguel Ángel|||0000-0001-7523-0212
  • Durán, Ignacio|||0000-0001-8571-7163
  • Gallardo Díaz, Enrique|||0000-0002-1375-3488
  • Rodríguez Sánchez, Ángel
  • Santander, Carmen
  • Sáez, Maria I.
  • Puente, J.|||0000-0002-6910-1331
  • Tudela, Julian
  • Martínez, Alberto
  • López-Andreo, María José|||0000-0002-7015-8132
  • Padilla, José
  • Lozano, Rebeca
  • Hervas, David|||0000-0003-0635-4961
  • Luo, Jun
  • De Giorgi, Ugo|||0000-0001-7520-2908
  • Castellano, Daniel|||0000-0002-9106-0687
  • Attard, Gerhardt
  • Grande, Enrique|||0000-0002-0134-4732
  • Gonzalez-Billalabeitia, Enrique|||0000-0003-3143-3143
There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). We conducted a phase II trial of enzalutamide in first-line chemo-naïve asymptomatic or minimally symptomatic mCRPC and analyzed the prognostic value of TMPRSS2-ERG and other biomarkers, including circulating tumor cells (CTCs), androgen receptor splice variant (AR-V7) in CTCs and plasma Androgen Receptor copy number gain (AR-gain). These biomarkers were correlated with treatment response and survival outcomes and developed a clinical-molecular prognostic model using penalized cox-proportional hazard model. This model was validated in an independent cohort. Ninety-eight patients were included. TMPRSS2-ERG fusion gene was detected in 32 patients with no differences observed in efficacy outcomes. CTC detection was associated with worse outcome and AR-V7 in CTCs was associated with increased rate of progression as best response. Plasma AR gain was strongly associated with an adverse outcome, with worse median prostate specific antigen (PSA)-PFS (4.2 vs. 14.7 m; p < 0.0001), rad-PFS (4.5 vs. 27.6 m; p < 0.0001), and OS (12.7 vs. 38.1 m; p < 0.0001). The clinical prognostic model developed in PREVAIL was validated (C-Index 0.70) and the addition of plasma AR (C-Index 0.79; p < 0.001) increased its prognostic ability. We generated a parsimonious model including alkaline phosphatase (ALP); PSA and AR gain (C-index 0.78) that was validated in an independent cohort. TMPRSS2-ERG detection did not correlate with differential activity of enzalutamide in first-line mCRPC. However, we observed that CTCs and plasma AR gain were the most relevant biomarkers.